The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Commentary|Articles|March 24, 2026
Thoracic Oncologists Preview Most Anticipated Abstracts From ELCC 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Read on to see what abstracts experts in the field of lung cancer are interested in learning more about at ELCC 2026 in Copenhagen, Denmark.
Advertisement
Advertisement
Ahead of this year’s European Lung Cancer Congress (ELCC), which will be held from March 25 to 28 in Copenhagen, Denmark, OncLive® asked leading oncologists in the lung cancer space to share what presentations they are most excited to learn more about during the meeting and why.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Advertisement
Advertisement